

# Stephen Opat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2542264/publications.pdf>

Version: 2024-02-01

119  
papers

6,492  
citations

186209

28  
h-index

69214

77  
g-index

119  
all docs

119  
docs citations

119  
times ranked

6126  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2014, 370, 1101-1110.	13.9	1,284
2	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019, 380, 2225-2236.	13.9	599
3	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1331-1344.	13.9	575
4	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
5	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , 2012, 119, 1963-1971.	0.6	313
6	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1433-1442.	5.1	306
7	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	0.6	281
8	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , 2019, 134, 851-859.	0.6	259
9	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1188-1200.	5.1	208
10	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3853-3865.	0.8	115
11	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2014, 111, 1072-1079.	2.9	113
12	ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2013, 368, 90-92.	13.9	110
13	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705.	0.6	108
14	The Recognition of HLA-B27 by Human CD4+ T Lymphocytes. <i>Journal of Immunology</i> , 2001, 167, 2619-2624.	0.4	106
15	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1530-1542.	5.1	91
16	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015, 126, 832-832.	0.6	90
17	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	0.6	83
18	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. <i>Blood</i> , 2020, 136, 2027-2037.	0.6	78

#	ARTICLE	IF	CITATIONS
19	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	2.5	77
20	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	1.4	68
21	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021, 5, 2577-2585.	2.5	60
22	Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. <i>Blood Advances</i> , 2016, 1, 31-35.	2.5	57
23	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
24	Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. <i>Neuro-Oncology</i> , 2013, 15, 1068-1073.	0.6	54
25	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	3.2	42
26	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019, 134, 35-35.	0.6	40
27	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. <i>Blood</i> , 2016, 128, 6-6.	0.6	40
28	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 123-123.	0.6	33
29	The oral iron chelator deferasirox inhibits $\text{NF-}\kappa\text{B}$ mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. <i>British Journal of Haematology</i> , 2015, 168, 576-582.	1.2	29
30	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 714-722.	3.2	27
31	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. <i>Annals of Hematology</i> , 2011, 90, 989-990.	0.8	27
32	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1329-1344.	1.3	27
33	Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU003 study. <i>British Journal of Haematology</i> , 2022, 196, 1209-1218.	1.2	24
34	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. <i>Pathology</i> , 2020, 52, 167-178.	0.3	23
35	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	0.6	23
36	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 642-642.	0.6	23

#	ARTICLE	IF	CITATIONS
37	Failure of rituximab monotherapy in lymphomatoid granulomatosis. <i>European Journal of Haematology</i> , 2005, 75, 172-173.	1.1	22
38	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	0.6	22
39	Disseminated Enteroviral Infection Associated with Obinutuzumab. <i>Emerging Infectious Diseases</i> , 2015, 21, 1661-1663.	2.0	21
40	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. <i>Blood</i> , 2013, 122, 6-6.	0.6	21
41	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7004-7004.	0.8	20
42	Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2016, 95, 667-668.	0.8	18
43	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BCB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. <i>Blood</i> , 2019, 134, 500-500.	0.6	18
44	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. <i>Blood</i> , 2015, 126, 496-496.	0.6	17
45	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4196-4196.	0.6	16
46	Allo-SCT for hematological malignancies in the setting of HIV. <i>Bone Marrow Transplantation</i> , 2010, 45, 584-586.	1.3	14
47	Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. <i>Journal of Medical Microbiology</i> , 2011, 60, 142-146.	0.7	14
48	Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. <i>HemaSphere</i> , 2019, 3, e187.	1.2	14
49	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. <i>Blood Advances</i> , 2022, 6, 1651-1660.	2.5	14
50	Bleeding and thrombotic events occur early in children on durable ventricular assist devices. <i>Thrombosis Research</i> , 2019, 173, 65-70.	0.8	13
51	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström's macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8007-8007.	0.8	13
52	<sc>WhiMSICAL</sc>: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. <i>American Journal of Hematology</i> , 2021, 96, E218-E222.	2.0	12
53	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 3472-3479.	2.5	12
54	Disseminated echovirus infection after allogeneic bone marrow transplantation. <i>Pathology</i> , 1997, 29, 424-425.	0.3	10

#	ARTICLE	IF	CITATIONS
55	High-dose cytarabine (24%g/m <sup>2</sup> ) in combination with idarubicin (HiDAC) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. <i>Internal Medicine Journal</i> , 2013, 43, 294-297.	0.5	10
56	First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. <i>Blood</i> , 2021, 138, 68-68.	0.6	10
57	High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 991-994.	1.2	9
58	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. <i>Blood</i> , 2016, 128, 1216-1216.	0.6	9
59	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. <i>Leukemia</i> , 2022, 36, 1654-1665.	3.3	9
60	Aplastic anaemia: autoimmune sequel of thymoma. <i>British Journal of Haematology</i> , 2009, 147, 591-591.	1.2	8
61	Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services. <i>Internal Medicine Journal</i> , 2016, 46, 964-969.	0.5	8
62	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. <i>Scientific Reports</i> , 2019, 9, 13544.	1.6	8
63	Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 1070-1080.	0.5	8
64	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 997-1003.	1.0	8
65	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013, 122, 86-86.	0.6	8
66	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054.	0.6	8
67	Failure of tofacitinib to achieve an objective response in a DDX3X-MLL10 T-lymphoblastic leukemia with activating JAK3 mutations. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004994.	0.5	7
68	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. <i>Blood</i> , 2019, 134, 1594-1594.	0.6	7
69	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. <i>Blood</i> , 2011, 118, 2599-2599.	0.6	7
70	Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. <i>Blood</i> , 2021, 138, 1419-1419.	0.6	7
71	Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 1592-1592.	0.6	6
72	Burkitt lymphoma in the setting of common variable immunodeficiency. <i>Annals of Hematology</i> , 2009, 88, 819-820.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. <i>Blood</i> , 2018, 131, 699-702.	0.6	5
74	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 253-260.	0.8	5
75	Frontline management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 422-433.	0.5	5
76	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 112-117.	0.6	5
77	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	0.6	5
78	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1964-1968.	0.6	4
79	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 4353-4353.	0.6	4
80	Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study. <i>Blood</i> , 2010, 116, 1776-1776.	0.6	4
81	Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study. <i>Blood</i> , 2011, 118, 5050-5050.	0.6	4
82	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. <i>Cancers</i> , 2022, 14, 2710.	1.7	4
83	Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 790-793.	1.2	4
84	A drop of vitriol: microspherocytosis following sulphuric acid exposure. <i>British Journal of Haematology</i> , 2008, 140, 596-596.	1.2	3
85	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.2	3
86	An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2021, 17, 371-387.	1.1	3
87	Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma. <i>Blood</i> , 2019, 134, 5256-5256.	0.6	3
88	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. <i>Blood</i> , 2019, 134, 1600-1600.	0.6	3
89	Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression. <i>Blood</i> , 2015, 126, 3457-3457.	0.6	3
90	An unusual case of indigestion: persistence of phagocytosed Auer rods in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2006, 133, 112-112.	1.2	2

#	ARTICLE	IF	CITATIONS
91	Factor XIII Assays. <i>Methods in Molecular Biology</i> , 2013, 992, 171-180.	0.4	2
92	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. <i>Journal of Clinical Oncology</i> , 2020, 38, 4221-4222.	0.8	2
93	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. <i>Blood</i> , 2019, 134, 3986-3986.	0.6	2
94	Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.. <i>Blood</i> , 2007, 110, 4941-4941.	0.6	2
95	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009, 114, 3944-3944.	0.6	2
96	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	0.6	2
97	Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy. <i>Blood</i> , 2016, 128, 2965-2965.	0.6	2
98	Antiplatelet therapy: present status and future prospects. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 1035-1040.	2.5	1
99	Oxidative haemolysis due to poppers. <i>British Journal of Haematology</i> , 2008, 142, 328-328.	1.2	1
100	Impact of coronavirus disease 2019 (COVID-19) pandemic isolation measures on the rate of nonâ€“COVID-19 infections in hematology patients. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 233-235.	1.0	1
101	A Description of the Type, Frequency and Severity of Infections Among Sixteen Patients Treated for T-Cell Lymphoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 123-129.	0.4	1
102	Safety of rapid injection of undiluted ferric carboxymaltose to patients with ironâ€“deficiency anaemia: a <sc>Phase II</sc> singleâ€“arm study. <i>Internal Medicine Journal</i> , 2021, 51, 1304-1311.	0.5	1
103	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. <i>Blood</i> , 2009, 114, 2923-2923.	0.6	1
104	Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDAll). <i>Blood</i> , 2010, 116, 4227-4227.	0.6	1
105	Salvage radiotherapy associates with durable response for a subset of patients with limited stage refractory DLBCL. <i>Blood Advances</i> , 2021, 5, 5112-5115.	2.5	1
106	Targeted Therapy in Leukaemia, Lymphoma and Myeloma. <i>Journal of Personalized Medicine</i> , 2022, 12, 74.	1.1	1
107	Bone marrow engraftment in pulmonary vessels. <i>British Journal of Haematology</i> , 2009, 146, 2-2.	1.2	0
108	The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research. <i>Internal Medicine Journal</i> , 2009, 39, 72-73.	0.5	0

#	ARTICLE	IF	CITATIONS
109	A case of ITP with cauda equina syndrome. <i>Annals of Hematology</i> , 2011, 90, 729-730.	0.8	0
110	A national pathology review committee for the lymphoma and related diseases registry. <i>Pathology</i> , 2018, 50, S107.	0.3	0
111	Concurrent <i>Mycobacterium tuberculosis</i> infection and nodal marginal zone lymphoma. <i>Pathology</i> , 2018, 50, 464-466.	0.3	0
112	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience. <i>Internal Medicine Journal</i> , 2021, 51, 1825-1834.	0.5	0
113	The Clinical Utility of the 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Trial in the Management of Patients with Von Willebrand Disease: A Retrospective Study.. <i>Blood</i> , 2006, 108, 1033-1033.	0.6	0
114	A Novel Fusion of RARA to the PRKAR1A Gene, Encoding the Regulatory Subunit Type-I Î± of Cyclic AMP Dependent Protein Kinase A, in a Variant Acute Promyelocytic Leukaemia.. <i>Blood</i> , 2006, 108, 2343-2343.	0.6	0
115	The Feasibility and Safety of Anticoagulation during Chemotherapy Associated Thrombocytopenia for Thrombotic Complications of Malignancy.. <i>Blood</i> , 2007, 110, 1872-1872.	0.6	0
116	The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.. <i>Blood</i> , 2007, 110, 4369-4369.	0.6	0
117	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). <i>Blood</i> , 2021, 138, 2532-2532.	0.6	0
118	A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial. <i>Blood</i> , 2021, 138, 4516-4516.	0.6	0
119	Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021, 138, 1455-1455.	0.6	0